Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267267 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,784
- Enrollment target
NCT00267267: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00267267 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,784 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (131% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267267, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,784 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
Interventions
- DRUG torcetrapib/atorvastatin
- DRUG ezetimibe/simvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,784 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Why NCT00267267 stopped before completion
NCT00267267 is an interventional study that assigns participants to a tested intervention. Its 1,784 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (131% higher).
The record links to 0 conditions, and to 2 interventions - of which torcetrapib/atorvastatin is the first listed.
NCT00267267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00267267 about?
NCT00267267 is a clinical study titled "A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.
What is the current status of trial NCT00267267?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,784 participants. The study started on 2006-01. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00267267?
The interventions under investigation include: torcetrapib/atorvastatin (DRUG), ezetimibe/simvastatin (DRUG).
Who is sponsoring clinical trial NCT00267267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00267267's enrollment target sits among peer trials
1,784 125th of 2000 higher than 1,876 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia